Medivation Inc  

(Public, NASDAQ:MDVN)   Watch this stock  
Find more results for mdvn
104.25
-0.47 (-0.45%)
Jan 28 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 102.82 - 106.22
52 week 54.37 - 117.23
Open 105.44
Vol / Avg. 1.18M/1.08M
Mkt cap 8.05B
P/E 73.78
Div/yield     -
EPS 1.41
Shares 77.62M
Beta 0.71
Inst. own 95%
Feb 25, 2015
Q4 2014 Medivation Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Jan 12, 2015
Medivation Inc at JPMorgan Healthcare Conference
Nov 19, 2014
Medivation Inc at Jefferies Global Healthcare Conference - London
Nov 11, 2014
Medivation Inc at Credit Suisse Healthcare Conference
Nov 6, 2014
Q3 2014 Medivation Inc Earnings Call
Nov 6, 2014
Q3 2014 Medivation Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin 38.90% -15.61%
Operating margin 45.83% -8.15%
EBITD margin - -6.88%
Return on average assets 56.80% -11.15%
Return on average equity 159.37% -56.59%
Employees 370 -
CDP Score - -

Address

36th Floor, 525 Market Street
SAN FRANCISCO, CA 94105
United States - Map
+1-415-5433470 (Phone)
+1-415-5433411 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Medivation, Inc. is a biopharmaceutical company focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. The Company selects technologies for development that can enter human studies within 12-18 months. It develops technologies without regard to therapeutic indication or therapeutic modality, such as small molecules, biologics and medical devices. The Company is engaged in various clinical trials. The Company�s PROSPER is a Phase III clinical trial. The Company�s TERRAIN trial and the STRIVE trial are two randomized, double-blind Phase II trials evaluating enzalutamide head-to-head versus bicalutamide in pre-chemotherapy CRPC patients. The Company�s PLATO is a Phase IV clinical trial. The Company and Astellas expanded the clinical development of enzalutamide to include breast cancer as a new indication.

Officers and directors

Kim D. Blickenstaff Independent Chairman of the Board
Age: 61
Bio & Compensation  - Reuters
David T. Hung M.D. President, Chief Executive Officer, Director
Age: 56
Bio & Compensation  - Reuters
Rick Bierly Chief Financial Officer, Principal Financial and Accounting Officer
Age: 58
Bio & Compensation  - Reuters
Stephen M. Kelsey M.D. Senior Vice President - New Projects
Age: 53
Bio & Compensation  - Reuters
Jennifer J. Rhodes Chief Compliance Officer, General Counsel, Corporate Secretary
Age: 44
Bio & Compensation  - Reuters
Dawn Svoronos Interim Chief Commercial Officer, Director
Age: 60
Bio & Compensation  - Reuters
Lynn Seely M.D. Chief Medical Officer
Age: 55
Bio & Compensation  - Reuters
C. Patrick Machado J.D. Director
Age: 50
Bio & Compensation  - Reuters
Kathryn E. Falberg Independent Director
Age: 53
Bio & Compensation  - Reuters
W. Anthony Vernon Independent Director
Age: 58
Bio & Compensation  - Reuters